About: Pharmacological Approach to Smoking Cessation: An Updated Review for Daily Clinical Practice

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Pharmacological Approach to Smoking Cessation: An Updated Review for Daily Clinical Practice Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Pharmacological Approach to Smoking Cessation: An Updated Review for Daily Clinical Practice
Creator	Filipponi, Andrea Giulietti, Federico Sarzani, Riccardo Spannella, Francesco Giordano, Piero Corrado Iacoacci, · Rosettani, Giulia
Source	Medline; PMC
abstract	Tobacco use is one of the major public health concerns and it is the most preventable cause of morbidity and mortality worldwide. Smoking cessation reduces subsequent cardiovascular events and mortality. Smoking is a real chronic disorder characterized by the development of an addiction status mainly due to nicotine. This condition makes the smokers generally unable to quit smoking without help. Different strategies are available to treat smoking dependence that include both non-pharmacological (behavioral counselling) and pharmacological therapies. Currently, it is well accepted that smoking cessation drugs are effective and safe in real-world settings. Nicotine replacement therapy (NRT), varenicline, bupropion and cytisine are the main pharmacological strategies available for smoking cessation. Their efficacy and safety have been proved even in patients with chronic cardiovascular disease. Each of these drugs has peculiar characteristics and the clinician should customize the smoking cessation strategy based on currently available scientific evidence and patient's preference, paying particular attention to those patients having specific cardiovascular and psychiatric comorbidities. The present document aims to summarize the current viable pharmacological strategies for smoking cessation, also discussing the controversial issue regarding the use of alternative tobacco products, in order to provide useful practical indications to all physicians, mainly to those involved in cardiovascular prevention.
has issue date	2020-06-23(xsd:dateTime)
bibo:doi	10.1007/s40292-020-00396-9
bibo:pmid	32578165
has license	cc-by-nc
sha1sum (hex)	3d73a967cfff536f3b940c6e0b70c72cee56f7bf
schema:url	https://doi.org/10.1007/s40292-020-00396-9
resource representing a document's title	Pharmacological Approach to Smoking Cessation: An Updated Review for Daily Clinical Practice
has PubMed Central identifier	PMC7309212
has PubMed identifier	32578165
schema:publication	High Blood Press Cardiovasc Prev
resource representing a document's body	covid:3d73a967cfff536f3b940c6e0b70c72cee56f7bf#body_text
is schema:about of	named entity 'addiction' named entity 'cardiovascular events' named entity 'chronic' named entity 'chronic' named entity 'summarize' named entity 'Review' named entity 'HEALTH CONCERNS' named entity 'CHARACTERISTICS' named entity 'STATUS' named entity 'CURRENTLY' named entity 'MAIN' named entity 'MORBIDITY AND MORTALITY' named entity 'SPECIFIC' named entity 'EFFECTIVE' named entity 'PREFERENCE' named entity 'MORTALITY' named entity 'PHYSICIANS' named entity 'CYTISINE' named entity 'PREVENTION' named entity 'DISCUSSING' named entity 'GENERALLY' named entity 'VIABLE' named entity 'CARDIOVASCULAR' named entity 'CHRONIC' named entity 'BASED' named entity 'ACCEPTED' named entity 'scientific evidence' named entity 'quit smoking' named entity 'provide' named entity 'pharmacological' named entity 'Bupropion' named entity 'aerosolization' named entity 'adverse events' named entity 'viral pandemic' named entity 'life studies' named entity 'NRT' named entity 'FDA' named entity 'route of administration' named entity 'tobacco consumption' named entity 'alprazolam' named entity 'enzyme' named entity 'stop smoking' named entity 'tobacco' named entity 'benzene' named entity 'Smoking cessation' named entity 'depressive disorders' named entity 'long-term' named entity 'pharmacological' named entity 'sustained-release' named entity 'adverse events' named entity 'sleep disorders' named entity 'risk management' named entity 'seizure' named entity 'cigarette smoking' named entity 'alternative' named entity 'safety' named entity 'drugs' named entity 'tobacco products' named entity 'pregnancy' named entity 'pharmacological' named entity 'smoking cessation' named entity 'pharmacological' named entity 'tobacco' named entity 'Nicotine addiction' named entity 'chronic obstructive pulmonary disease' named entity 'bupropion' named entity 'oral mucosa' named entity 'Transdermal nicotine' named entity 'sleep disorders' named entity 'pathogenesis' named entity 'excreted' named entity 'withdrawal syndrome' named entity 'tobacco products' named entity 'anxiolytics' named entity '12 weeks'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software